Abstract: Polypeptide having an amino acid sequence selected from at least 70% sequence identity to any one of domains 1 to 14 of LEKTI, SPINK6 or SPINK9-polypeptide for use in the treatment of a viral infection with a virus, in the infection of which serine proteinases are involved, and slowing down the spread of infection of said virus.

Abstract: A pharmaceutical composition containing human ribonuclease 1 is disclosed. The molecule according to the invention (or the analogous variants) is suitable for use as a medicament for therapy of renal diseases of various aetiologies. The drug according to the invention causes regeneration of glomerular podocytes. The molecule according to the invention can be further used by analytical determination of blood concentration as a marker of disease progression of renal syndromes and for prognosis and prevention of renal insufficiency as a valuable factor of laboratory medicine.

Abstract: A polypeptide having the general amino acid sequence written in the single letter code Z1X1X2X3X4X5QX7APX10X11SZ3, wherein X1=V, M or L, in particular L, X2=V, L or M, in particular V, X3=R, K or C, in particular R, X4=Y or W, in particular Y, X5=S or T, in particular T, X7=K, C or R, in particular K, X10=Q or C, in particular Q, and X11=V, M or F, in particular V and Z3=0, or Z4, wherein Z4=0 or is a modification of the C-terminal carboxyl group of the peptide chain, which modification forms together with the carboxyl group of the C-terminal amino acid of the peptide a moiety having the structure —C(O)—O—R1 or —C(O)—NR2R3, wherein R1 is a substituted or unsubstituted alkyl, aryl, aralkyl, cyclo alkyl and heterocyclo alkyl group.

Abstract: A polypeptide having the general amino acid sequence Z1IX2RWX5X6KX8PX10X11SZ3, wherein X2=V, M or L, X5=S or T, X6=K or R, X8=V, M, L or F, X10=Q or C, X11=V, M or F; Z1=0, Z2, or pyro glutamate, wherein Z2 is a modification of the amino group of the N-terminal amino acid having the structure —NR2R3 wherein R2 and/or R3 are independently from each other H or an acyl, alkyl, aryl, aralkyl, cyclo alkyl and heterocyclo alkyl group; Z3=0, or Z4, wherein Z4 is a modification of the carboxyl group of the C-terminal amino acid having the structure —C(O)—O—R1 or —C(O)—NR2R3, wherein R1 is an alkyl, aryl, aralkyl, cyclo alkyl and heterocyclo alkyl group; and R2 and R3 are defined as above.

Abstract: The invention relates to a polypeptide having the sequence Z1-Gln-Ala-Lys-Ile-Lys-Gln-Ile-Ile-Asn-Met-Trp-Gln-Z2. The polypeptide is used for retroviral transfection/transduction.

Abstract: A polypeptide having the general amino acid sequence written in the single letter code Z1IX2RWX5X6KX8PX10X11SZ3, wherein X2=V, M or L, in particular L, X5=S or T, X6=K or R, in particular R, X8=V, M, L or F, in particular M, X10=Q or C, in particular C, X11=V, M or F, in particular V; Z1=O, Z2, or pyro glutamate, wherein Z2= is a modification of the N-terminal nitrogen atom of the peptide chain which modification forms together with the amino group of the N-terminal amino acid of the peptide a moiety having the structure —NR2R3 wherein R2 and/or R3 are independently from each other H or a substituted or unsubstituted acyl, alkyl, aryl, aralkyl, cyclo alkyl and heterocyclo alkyl group; Z3=O, or Z4, wherein Z4= is a modification of the C-terminal carboxyl group of the peptide chain, which modification forms together with the carboxyl group of the C-terminal amino acid of the peptide a moiety having the structure —C(O)—O—R1 or —C(O)—NR2R3, wherein R1 is a substituted or unsubstituted alkyl, aryl, ara

Abstract: Polypeptide having the sequence

Abstract: A peptide effective in blocking the CXC-chemokine receptor 4 (CXCR4) mediated HIV-1 NL4-3 (X4-tropic) infection with an IC50 value of less than 50 ?M.

Abstract: An N-terminally protected peptide having the sequence (SEQ?ID?NO:?1) X-Glu-Cys-Lys-Ile-Lys-Gln-Ile-Ile-Asn-Met-Trp-Gln, wherein X is a group protecting the N-terminal of the peptide.

Abstract: An N-terminally protected peptide having the sequence (SEQ ID NO: 1) X-Glu-Cys-Lys-Ile-Lys-Gln-Ile-Ile-Asn-Met-Trp-Gln, wherein X is a group protecting the N-terminal of the peptide.

Abstract: Use of urodilatin for preparing a medicament for the treatment of cardiovascular, renal, pulmonary and neuronal syndromes while avoiding a rebound, wherein said medicament for the delivery of urodilatin is suitable in a first quantity for a first period of at least 48 hours, followed by delivery over a second period of at least 12 hours with successive reduction of said first quantity continuously or gradually to 0 ng/kg/min.

Abstract: The present invention relates to the use of a natriurectic peptide, such as urodilatin, for treating a patient suffering from heart failure, such as acute decompensated heart failure. Preferably, a composition comprising an effective amount of urodilatin is intravenously administered to the patient continuously through a time period of at least 24 hours and up to 120 hours, preferably at least 48 hours.

Abstract: Use of urodilatin for preparing a medicament for the treatment of cardiovascular, renal, pulmonary and neuronal syndromes while avoiding a rebound, wherein said medicament for the delivery of urodilatin is suitable in a first quantity for a first period of at least 48 hours, followed by delivery over a second period of at least 12 hours with successive reduction of said first quantity continuously or gradually to 0 ng/kg/min.

Abstract: A process for preparing human relaxin-2 having the following amino acid sequence: A chain: (SEQ?ID?NO:?1) pGlu-Leu-Tyr-Ser-Ala-Leu-Ala-Asn-Lys-Cys-Cys-His- Val-Gly-Cys-Thr-Lys-Arg-Ser-Leu-Ala-Arg-Phe-Cys B chain: (SEQ?ID?NO:?2) Asp-Ser-Trp-Met-Glu-Glu-Val-Ile-Lys-Leu-Cys-Gly- Arg-Glu-Leu-Val-Arg-Ala-Gln-Ile-Ala-Ile-Cys-Gly- Met-Ser-Thr-Trp-Ser; comprising the following steps: providing the amino acids necessary for the synthesis of the A and B chains with usual protective groups, wherein the cysteines are employed as trityl-protected amino acids (L-Cys(Trt)-OH); effecting a chromatographic purification of the individual chains A and B after the solid state synthesis; followed by the simultaneous folding and combination of the individual chains A and B in ammonium hydrogencarbonate buffer at pH 7.9 to 8.4; and subsequent purification of the relaxin-2 formed.

Abstract: An N-terminally protected peptide having the sequence (SEQ ID NO: 1) X-Glu-Cys-Lys-Ile-Lys-Gln-Ile-Ile-Asn-Met-Trp-Gln, wherein X is a group protecting the N-terminal of the peptide.

Abstract: The present invention relates to the use of a natriurectic peptide, such as urodilatin, for treating a patient suffering from heart failure, such as acute decompensated heart failure. Preferably, a composition comprising an effective amount of urodilatin is intravenously administered to the patient continuously through a time period of at least 24 hours and up to 120 hours, preferably at least 48 hours.

Abstract: A peptide effective in blocking the CXC-chemokine receptor 4 (CXCR4) mediated HIV-1 NL4-3 (X4-tropic) infection with an IC50 value of less than 50 ?M.

Abstract: The present invention relates to the use of a natriurectic peptide, such as urodilatin, for treating a patient suffering from heart failure, such as acute decompensated heart failure. Preferably, a composition comprising an effective amount of urodilatin is intravenously administered to the patient continuously through a time period of at least 24 hours and up to 120 hours, preferably at least 48 hours.

Abstract: A peptide having the following amino acid sequence: Z1-LVRYTKKVPQVSTPTL-Z2(ALB-408) and its biologically active fragments and/or variants and/or derivatives, especially amidated, acetylated, sulfated, phosphorylated and/or glycosylated derivatives, and peptides obtainable by multiple synthesis which have the biological activity of ALB408-423; wherein Z represents number of from 0 to 10 amino acid residues.

Abstract: The present invention relates to the use of a natriurectic peptide, such as urodilatin, for treating a patient suffering from heart failure, such as acute decompensated heart failure. Preferably, a composition comprising an effective amount of urodilatin is intravenously administered to the patient continuously through a time period of at least 24 hours and up to 120 hours, preferably at least 48 hours.